Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2021-02-03 Regulatory Filings
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-02-03 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is titled "Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933" filed with the SEC. It is a registration statement for an initial public offering (IPO) of common stock by Sana Biotechnology, Inc. The text includes detailed information typical of an S-1 filing such as company overview, risk factors, use of proceeds, capitalization, management discussion and analysis, executive compensation, principal stockholders, and underwriting details. The S-1 form is a registration statement used for securities offerings and is not a financial report like an annual or quarterly report, nor is it a proxy, earnings release, or other categories listed. It is a capital markets filing related to the offering of securities. The closest fitting category from the provided list is "Capital/Financing Update (CAP)" which covers updates on company fundraising and financing activities. Given the document is a detailed registration statement for an IPO, the classification as CAP is appropriate with high confidence.
2021-02-03 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is titled as an Amendment No. 2 to Form S-1 Registration Statement filed with the SEC, dated February 2, 2021. It is a registration statement under the Securities Act of 1933 for Sana Biotechnology, Inc. The text includes details about the offering of common stock, underwriting, risk factors, management discussion and analysis, business overview, and other typical sections of an IPO registration statement. Form S-1 is a registration document used for initial public offerings and is not a financial report like an annual or quarterly report. It is a capital markets filing related to the company's fundraising and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual filing, not just an announcement or certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2021-02-02 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a letter from Sana Biotechnology, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 of Regulation C under the Securities Act of 1933 and specifically mentions the Registration Statement on Form S-1 (Registration No. 333-252061). This is a formal communication related to the registration and offering of securities, which is a capital raising activity. The document is not a full report but a correspondence requesting an administrative action related to a financing filing. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication or a certification, so RPA or RNS are less appropriate.
2021-02-01 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC responding to comments on a Registration Statement on Form S-1. It references amendments to the Registration Statement, responses to SEC comment letters, and revisions to disclosures. The document is correspondence related to a regulatory filing process rather than the filing itself or a financial report. It is short (3115 characters) and primarily a response letter, not containing financial statements or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory correspondence and filings that do not fit other categories.
2021-01-28 English
AMENDMENT NO. 1 TO FORM S-1
Capital/Financing Update Classification · 100% confidence The document is titled "Amendment No. 1 to Form S-1" and is a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the company's business, risk factors, management, financial data, and offering details. Form S-1 is used for initial public offerings (IPOs) and related securities registration. This is a capital markets filing related to the company's fundraising and securities offering, not a financial report, earnings release, or management discussion. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full amendment filing, not just an announcement or certification, supporting a high confidence classification.
2021-01-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.